Trxade Health Inc (NASDAQ: MEDS) has experienced a rise in its stock price by 26.16 compared to its previous closing price of 6.59. However, the company has seen a gain of 39.95% in its stock price over the last five trading days. globenewswire.com reported 2024-05-29 that TAMPA, FL, May 29, 2024 (GLOBE NEWSWIRE) — TRxADE HEALTH, Inc. (Nasdaq: MEDS) (the “Company”), announced that, on May 23, 2024, the Company received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (“Nasdaq”) indicating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the period ending March 31, 2024 (the “Form 10-Q”), the Company is not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission.
Is It Worth Investing in Trxade Health Inc (NASDAQ: MEDS) Right Now?
Company’s 36-month beta value is 2.14.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MEDS is 0.51M, and currently, short sellers hold a 1.96% ratio of that floaft. The average trading volume of MEDS on June 17, 2024 was 35.96K shares.
MEDS’s Market Performance
MEDS’s stock has seen a 39.95% increase for the week, with a 48.04% rise in the past month and a -36.09% fall in the past quarter. The volatility ratio for the week is 7.99%, and the volatility levels for the past 30 days are at 7.84% for Trxade Health Inc The simple moving average for the past 20 days is 31.63% for MEDS’s stock, with a 43.51% simple moving average for the past 200 days.
MEDS Trading at 26.90% from the 50-Day Moving Average
After a stumble in the market that brought MEDS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.03% of loss for the given period.
Volatility was left at 7.84%, however, over the last 30 days, the volatility rate increased by 7.99%, as shares surge +34.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.08% lower at present.
During the last 5 trading sessions, MEDS rose by +31.85%, which changed the moving average for the period of 200-days by +16.30% in comparison to the 20-day moving average, which settled at $6.42. In addition, Trxade Health Inc saw 139.82% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MEDS
Current profitability levels for the company are sitting at:
- -0.87 for the present operating margin
- 0.3 for the gross margin
The net margin for Trxade Health Inc stands at -1.94. The total capital return value is set at -7.92. Equity return is now at value -2173.62, with -174.70 for asset returns.
Based on Trxade Health Inc (MEDS), the company’s capital structure generated 0.93 points at debt to capital in total, while cash flow to debt ratio is standing at -0.29. The debt to equity ratio resting at 13.1. The interest coverage ratio of the stock is -6.45.
Currently, EBITDA for the company is -6.19 million with net debt to EBITDA at -1.04. When we switch over and look at the enterprise to sales, we see a ratio of 2.15. The receivables turnover for the company is 3.57for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.24.
Conclusion
In a nutshell, Trxade Health Inc (MEDS) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
